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Prediagnostic serum glucose and lipids in
relation to survival in breast cancer
patients: a competing risk analysis
Wahyu Wulaningsih1*†, Mariam Vahdaninia1†, Mark Rowley2, Lars Holmberg1,3,4, Hans Garmo1,4, Håkan Malmstrom5,
Mats Lambe4,6, Niklas Hammar5,7, Göran Walldius8, Ingmar Jungner9, Anthonius C. Coolen2 and
Mieke Van Hemelrijck1,5
Abstract
Background: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their
association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem.
Methods: We assessed serum glucose, triglycerides (TG) and total cholesterol (TC) measured prospectively
3 months to 3 years before diagnosis in 1798 Swedish women diagnosed with any type of BC between 1985 and
1999. In addition to using Cox regression, we employed latent class proportional hazards models to capture any
heterogeneity of associations between these markers and BC death. The latter method was extended to include
the primary outcome (BC death) and competing outcomes (CV death and death from other causes), allowing latent
class-specific hazard estimation for cause-specific deaths.
Results: A lack of association between prediagnostic glucose, TG or TC with BC death was observed with Cox
regression. With latent class proportional hazards model, two latent classes (Class I and II) were suggested. Class I,
comprising the majority (81.5 %) of BC patients, had an increased risk of BC death following higher TG levels
(HR: 1.87, 95 % CI: 1.01–3.45 for every log TG increase). Lower overall survival was observed in Class II, but no
association for BC death was found. On the other hand, TC positively corresponded to CV death in Class II,
and similarly, glucose to death from other causes.
Conclusion: Addressing cohort heterogeneity in relation to BC survival is important in understanding the
relationship between metabolic markers and cause-specific death in presence of competing outcomes.
Keywords: Breast cancer, Glucose, Lipid, Competing risk, Survival, Latent class
Background
Disorders in glucose and lipid metabolism have been
suggested as a mechanism linking obesity and breast
cancer (BC) [1, 2]. In addition to their roles in carcino-
genesis, increasing evidence suggests that abnormal
levels of serum glucose and lipids impact survival in BC
patients [3–5]. Most of these studies investigated all-
cause mortality as the outcome of interest. When BC-
specific death is studied as the primary outcome, infor-
mation on other causes of death such as cardiovascular
(CV) disease is rarely addressed in the analysis [4]. Given
the high survivorship of BC [6, 7] and how glucose and
lipids are linked to CV mortality [8, 9], one must con-
sider the possibility of competing risks. For instance, a
competing risk situation arises when a person has a
common risk factor of dying from both BC and CV dis-
ease (and other causes), so that any earlier outcome will
‘prevent’ the individual from developing others [10].
Interpreting survival data thus becomes difficult because
commonly used methods, i.e., Kaplan-Meier survival es-
timates and Cox’ proportional hazards, rely on the
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assumption of non-informative censoring. When this as-
sumption is met, any censoring due to non-primary
events does not affect one’s risk of developing the pri-
mary outcome, thus such a risk is proportional to the
levels of risk factors or covariates observed. However,
when competing risks are an issue a heterogeneous asso-
ciation between covariates and the primary outcome may
exist, reflecting subpopulations or classes with different
mortality risk profiles. This heterogeneity within a cohort
is scarcely studied in the context of cancer survival.
The objectives of the present study were to investigate
how prediagnostic serum glucose, triglycerides (TG) and
total cholesterol (TC) are associated to BC death, and to
capture heterogeneity of associations between these
markers and BC death which may indicate a competing
risk situation. We used prospectively collected data from
the Apolipoprotein Mortality Risk (AMORIS) Study and
utilised 1) Cox proportional hazards model to assess the
link between serum glucose, TG and TC with BC death,
and 2) latent class proportional hazards models with BC
death as the primary outcome and deaths from CV dis-
ease and other causes as non-primary outcomes to cap-
ture heterogeneity of BC mortality risk.
Methods
Study population
The Apolipoprotein Mortality Risk (AMORIS) Study has
been described in detail elsewhere [11, 12]. Briefly, the
recently updated AMORIS database comprises 812,073
individuals with blood samples sent for laboratory test-
ing to the Central Automation Laboratory (CALAB) in
Stockholm, Sweden. Individuals recruited were mainly
from the greater Stockholm area, and either healthy and
having laboratory testing as a part of general check-up,
or outpatients referred for laboratory testing. None of
the participants were inpatients at the time the samples
were analysed. In the AMORIS study, the CALAB data-
base was linked to Swedish national registries such as
the Swedish National Cancer Register, the Hospital Dis-
charge Register, the Cause of Death Register, the con-
secutive Swedish Censuses during 1970–1990, and the
National Register of Emigration using the Swedish 10-
digit personal identity number, providing complete
follow-up information until 31 December 2011.
From the AMORIS population, we selected 1798
women with an incident diagnosis of BC between 1985
and 1999 who had baseline measurements of serum glu-
cose, TG and TC within 3 months to 3 years prior to diag-
nosis. Diagnosis of BC was obtained from the Swedish
National Cancer Register using the Seventh Revision of
the International Classification of Diseases code (ICD-
7 code: 174), and information on cause-specific deaths
(BC death, CV death) was obtained from the Swedish
Cause of Death Register. Follow-up time was defined as
the time from diagnosis until death from any causes, emi-
gration, or end of study (31 December 2011), which-
ever occurred first. The ethics review board of the
Karolinska Institute approved the study, and permits
were obtained from Swedish Data Inspection to cor-
relate laboratory results with Swedish national regis-
ters. Anonymity of participants was maintained
throughout the study. Participant informed consent
was not required for this register linkage study [13].
Serum glucose and lipids measurements
Serum levels of glucose (mmol/L), TG (mmol/L), and
TC (mmol/L) were measured enzymatically with stand-
ard methods [12]. All three markers were measured at
the same day, within 3 months to 3 years prior to diag-
nosis. This timeframe was selected to capture metabolic
derangements during ongoing malignancy process while
excluding effects of breast cancer diagnostic or treat-
ment interventions. All measurements were fully auto-
mated with automatic calibration and performed at one
accredited laboratory [11]. TG levels were not normally
distributed, and therefore we used log-transformed
values of all markers in addition to their quartiles in the
analysis.
Covariates
Information on fasting status at baseline measurements
(fasting, non-fasting, unknown) was obtained from the
CALAB database. Socioeconomic status (SES; white col-
lar, blue collar, unemployed or unknown) was based on
occupational groups in the Population and Housing
Census and classified all gainfully employed subjects as
manual workers and non-manual workers, which were
referred to as blue collar and white collar workers, re-
spectively [14].
Statistical analysis
We began by employing multivariable Cox proportional
hazards regression to assess the association between log-
transformed values and quartiles of glucose, TG and TC
and the risk of BC death as the primary outcome, CV
death and other death as competing outcomes. Adjust-
ment was performed for potential confounders including
age at diagnosis, SES, and fasting status at baseline mea-
surements. Glucose, TG and TC were each analysed
while adjusting for the other two markers as continuous
variables. The proportionality of hazards assumption
was met after assessing time-varying covariates which
were the cross-products of each variable and time. To
assess any potential competing risk, we used cumulative
incidence functions to display the proportions of deaths
from BC, CV disease and other causes by quartiles of
glucose, TG, and TC.
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We further investigated the association between serum
glucose, TG and TC and BC survival using a latent class
proportional hazards model. Latent class analysis has
been used to identify different classes or latent variables
within a given population which underlies the pattern of
association between observed covariates [15]. In medical
research, the latent class variable has been incorporated
into various regression analyses, including Cox propor-
tional hazards models, to allow identification of sub-
groups with different risk profiles [16–18]. To capture
heterogeneity in the context of BC survival, we extended
the proportional hazards model to encompass the latent
class variable in addition to glucose, TG and TC, which
were assessed as continuous variables. The number of
latent classes present in the cohort was identified with
Bayesian model selection. To assess BC-specific death
whilst accounting for competing risks, we incorporated
BC death as the primary outcome and deaths from CV
disease and other causes as non-primary outcomes into
the latent class proportional hazards model. Class mem-
bership probabilities were retrospectively predicted
based on associations between covariates and events. In-
dependent samples T-test and Chi2 test were used to as-
sess differences in characteristics of study participants by
predicted class membership. We further displayed latent
class-specific cumulative incidence functions for BC, CV
and other death by quartiles of the three markers. Fi-
nally, hazard ratios for BC, CV and other death by levels
of glucose, TG, and TC were estimated for each latent
class according to the maximum-a-posteriori (MAP)
likelihood, which took into account all three outcomes
[19]. More details on the latent class survival analysis
are available as Additional file 1.
Descriptive analysis and Cox proportional hazards
model were performed with Statistical Analysis Software
(SAS) release 9.3 (SAS Institute, Cary, NC) and R
Table 1 Descriptive characteristics of study participants overall and by causes of death
All BC Overall death BC death CV death Other death
(n = 1798) (n = 861) (n = 425) (n = 179) (n = 257)
No. % No. % No. % No. % No. %
Age, years
Mean 58.1 62.4 56.5 71 66.2
SD 11.8 13.2 12.5 10.3 11.4
Follow-up time, years
Mean 13.3 8.3 6.4 9.3 10.6
SD 6.9 5.9 5.0 6.5 6.0
Interval between measurements and diagnosis, months
Mean 18.3 18.1 18.3 17.6 17.9
SD 9.2 9.2 9.0 9.5 9.2
SES
White collar 648 36.0 235 27.3 147 34.6 30 16.8 58 22.6
Blue collar 894 49.7 405 47.0 222 52.2 61 34.1 122 47.5
Unemployed or unknown 256 14.3 221 25.7 56 13.2 88 49.1 77 29.9
Fasting status
Fasting 1027 57.1 508 59.0 242 56.9 107 59.7 159 62.9
Non-fasting 568 31.6 254 29.5 133 31.3 52 29.1 69 26.8
Unknown 203 11.3 99 11.5 50 11.8 20 11.2 29 11.3
Glucose, mmol/L
Mean 5.1 5.2 5.0 5.5 5.4
SD 1.2 1.4 1.0 1.2 1.8
TG, mmol/L
Mean 1.3 1.4 1.3 1.6 1.4
SD 0.8 0.9 0.9 0.9 0.8
TC, mmol/L
Mean 5.9 6.1 5.9 6.5 6.2
SD 1.2 0.8 1.2 1.2 1.2
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version 3.0.2 (R Project for Statistical Computing,
Vienna, Austria). Latent class proportional hazards
model were performed with Advanced Survival Analysis
software version 0.2.16 (A.C.C. Coolen, M. Rowley, M.
Inoue, London, UK).
Results
At the end of follow up (mean: 13 years), a total of 861
(47.9 %) study participants were deceased. Among these
women, 425 died from BC, 179 from CV disease, and
257 from other causes. The mean age of all participants
was 58 at BC diagnosis. Levels of glucose, TG, and TC
were highest in those dying from CV disease, whereas
women who died from BC had lower levels of the three
markers compared to all women dying during follow-up
period (Table 1).
When conventional Cox proportional hazards regres-
sion was performed, no strong association was observed
between glucose, TG, and TC and risk of dying from BC
(Table 2). On the other hand, positive associations were
observed between TG and CV death, as well as glucose
and CV death. No association was observed for other
causes of death. Proportions of deaths from each causes
by quartiles of glucose, TG, TC was further displayed
using the cumulative incidence functions. As shown in
Fig. 1, the proportion of women dying from CV disease
markedly increased with higher quartiles of the markers,
whilst deaths from BC are less frequent with higher
quartiles of the markers. This indicated CV death as a
competing event.
Our next analysis extended the proportional hazards
model to include latent class variables and assess pri-
mary and non-primary outcomes. Bayesian model
Table 2 Hazard ratios of death from BC, CV disease and other causes by levels of glucose, TG, and TC
No. of
subjects
BC death CV death Other death
No. of events HRa 95 % CI No. of events HRa 95 % CI No. of events HRa 95 % CI
Glucose, mmol/Lb
Continuous log 0.96 0.58, 1.59 2.48 1.24, 4.96 2.09 1.16, 3.76
Quartiles
< 4.50 393 98 1 21 1 45 1
4.50–4.90 413 116 0.98 0.75, 1.29 36 1.27 0.74, 2.19 63 1.12 0.76, 1.64
4.90–5.30 363 96 0.95 0.72, 1.27 41 1.28 0.75, 2.19 50 0.87 0.58, 1.30
≥ 5.30 416 115 0.98 0.74, 1.29 80 1.67 1.02, 2.73 100 1.32 0.92, 1.89
Ptrend 0.83 0.03 0.20
TG, mmol/Lc
Continuous log 1.21 0.98, 1.48 1.58 1.17, 2.13 1.32 1.02, 1.71
Quartiles
< 0.70 297 81 1 12 1 24 1
0.70–1.00 491 102 0.77 0.57, 1.04 34 0.91 0.46, 1.77 56 0.96 0.59, 1.57
1.00–1.60 555 132 0.97 0.72, 1.29 52 1.10 0.58, 2.08 95 1.28 0.81, 2.03
≥ 1.60 455 110 1.05 0.76, 1.45 80 1.53 0.81, 2.90 83 1.22 0.75, 1.98
Ptrend 0.35 0.01 0.16
TC, mmol/Ld
Continuous log 0.72 0.40, 1.28 2.04 0.83, 5.04 0.67 0.32, 1.42
Quartiles
< 5.20 443 119 1 16 1 38 1
5.20–5.80 403 94 0.87 0.66, 1.14 37 1.52 0.83, 2.76 60 1.18 0.78, 1.79
5.80–6.60 470 102 0.79 0.60, 1.04 40 1.26 0.70, 2.27 75 1.06 0.72, 1.58
≥ 6.60 482 110 0.85 0.64, 1.15 85 1.74 0.99, 3.04 85 0.92 0.61, 1.38
Ptrend 0.21 0.08 0.38
aAdjusted for age at diagnosis, SES (white collar, blue collar, unemployed or unknown), fasting status (fasting, non-fasting, unknown), glucose (continuous), TG
(continuous), and TC (continuous)
Not adjusted for bglucose, cTG, dTC
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selection identified two latent classes in this study popu-
lation. Retrospective analysis for class membership prob-
ability suggested that 81.5 % women were more likely to
be members of Class I, while the other 18.5 % belonged
to Class II. We further assessed baseline characteristics
of study participants in relation to the most probable la-
tent class they were assigned to. Younger average age
was observed in Class I compared to Class II, and a dif-
ference in socio-economic status between classes was in-
dicated (Table 3). With regards to clinical outcomes, no
difference in proportions of women who died from BC
was found between the two classes. However, statistically
significantly higher overall mortality rate from CV dis-
ease and other causes were seen in Class II.
We further investigated difference in survivals between
latent classes by displaying cumulative incidence func-
tions for different causes of death by quartiles of glucose,
TG, and TC (Fig. 2). Higher overall mortality was seen
in Class II compared to Class I. In Class I, most patients
died from BC, whereas in Class II, most died from other
causes apart from BC and CV death. Increasing absolute
numbers of deaths from BC, CV, and other causes were
seen with higher levels of all three markers in Class I, al-
though there was no marked difference in relative mor-
tality rates between each cause of death. On the other
hand, marked differences in relative proportions of
women dying from the three different causes were seen
across levels of markers in Class II. For instance, BC
deaths were common amongst women in the lowest
quartiles of glucose, TG, and TC, but contributed little
to total deaths in those with highest levels of the
markers. More women died from CV disease with higher
TC, and a similar association was seen between glucose
and death from other causes. Finally, the risk of different
causes of death was quantitatively assessed by obtaining
class-specific hazard estimates. As seen in Table 4, log-
transformed TG corresponded to an increased risk of
dying from BC in Class I, with a hazard ratio of 1.87
(95 % CI: 1.01–3.45). No statistically significant associa-
tions with BC death were observed for other markers or
among women in Class II. In agreement with class-
specific cumulative incidence functions, women in Class
II had a higher risk of CV death with higher TC and a
higher risk of other death with higher glucose levels.
Discussion
We performed Cox regression and a latent class pro-
portional hazards analysis to assess the association
between prediagnostic markers of glucose and lipid
metabolism and death from BC in female BC patients.
The latter method accounted for CV death and other
death as competing risks. With the conventional Cox
BC death
CV death
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Fig. 1 Stacked cumulative risk of death from BC, CV disease, and other causes, stratified by quartiles of glucose, TG and TC
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proportional hazards model, a lack of association was
observed between the three markers and BC death.
However, CV death was shown as a competing event.
When latent class proportional hazards analysis were
performed, we found two distinct latent classes within
our cohort, reflecting different susceptibilities of dying
from BC based on their baseline characteristics. Class I,
comprising the majority of the study population, is associ-
ated with an increased risk of BC death following higher
TG levels. Overall survival is worse in Class II, among
which higher TC levels were associated with an increased
risk CV death and higher glucose with risk of death from
other causes. No association between the three markers
and BC death was seen in Class II.
Metabolisms of glucose and lipid have been implicated
in many chronic diseases. In the context of cancer, an
array of evidence has linked increased BC incidence with
aberrant levels of circulating glucose, TG and TC at
baseline [20–22]. Abnormal levels of these markers are
also associated with CV disease, which is the most com-
mon cause of death in general population [8, 9]. This
has also been demonstrated in our study, as both glu-
cose and TG were associated with a higher risk of CV
death, and the associations were stronger than those
with BC death. Several biological mechanisms are sug-
gested to underlie this common link, such as chronic in-
flammation and insulin resistance, which may drive
atherogenesis, cellular proliferation and angiogenesis
[2, 23, 24]. These shared metabolic pathways may
thus result in a competing risks situation, where indi-
viduals with similar sets of risk factors are equally at
risk of dying from both BC and CV disease. In this
case, a heterogeneous association between glucose
and lipid markers and BC death may be observed,
which represents subpopulations or latent classes with
different mortality risk profiles. However, this hetero-
geneity in survival data is not addressed by common
analytical methods in cancer epidemiology.
Cox proportional hazards regression and latent classes
proportional hazards model differ fundamentally in the
assumptions made regarding risk correlations. In Cox,
non-informative censoring is assumed, which leads to
the assumption of independence or no correlation be-
tween event times when multiple events are observed.
However, in the real-world clinical observation, such as-
sumptions are rarely assessable and sometimes inaccur-
ate. The latent class proportional hazards model allows
for the presence of heterogeneity underlying any ob-
served risk associations [16] and predicts optimal pa-
rameters based on the most probable substructure of the
study population. In our study, this resulted in an opti-
mal model with two latent classes. Overall survival was
lower in Class II than Class I, which indicates the im-
portance of taking into account risk associations when
investigating biological markers in relation to cancer
survival.
We found TG to be associated with early death from
BC in Class I. This suggests an importance of lipid me-
tabolism in disease progression in a relevant subset of
BC patients, which warrants further mechanistic investi-
gation. No statistically significant association with BC
death was observed for glucose and TC, although among
Class II they were associated with higher risks of dying
from other causes and CV disease, respectively. Previous
studies have reported a null association for TG and TC
in relation to all-cause mortality [25] and BC-specific
death [26], which is similar to our findings using Cox re-
gression and in Class II as assessed by latent classes pro-
portional hazards model. Likewise, a lack of association
with overall death has been reported for glucose [4, 5].
Although Class I comprised the majority of all women
Table 3 Characteristics of study participants and causes of
death by predicted class membership
BC P-value
Class I Class II
(N = 1466) (N = 332)
N % N %
Age, years <0.0001
Mean 57.6 60.5
SD 10.9 15.0
SES <0.0001
White collar 554 37.8 94 28.3
Blue collar 739 50.4 155 46.7
Unemployed or missing 173 11.8 83 25.0
Fasting status 0.55
Fasting 827 56.4 200 60.2
Non-fasting 477 32.5 91 27.4
Missing 162 11.1 41 12.4
Glucose (mmol/l) 0.08
Mean 5.1 5
SD 1.3 1.1
TG (mmol/l) 0.32
Mean 1.3 1.3
SD 0.8 0.8
TC (mmol/l) 0.34
Mean 5.9 6.0
SD 1.2 1.2
BC death 342 23.3 83 25.0 0.52
CV death 129 8.8 50 15.1 <0.0001
Other death 60 4.1 197 59.3 <0.0001
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Fig. 2 Stacked cumulative risk of death from BC, CV disease, and other causes for each latent class, stratified by quartiles of glucose, TG and TC
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studied, it is possible that the positive association be-
tween TG and Class I was diluted in the overall cohort,
resulting in a weaker association. Therefore, it is import-
ant to consider cohort heterogeneity in assessing this
relationship.
The strength of this study lies in the survival analysis
method used to address competing risks, as well as the
relatively large cohort with follow-up information for all
participants (up to 25 years). The population in the
AMORIS study was selected by analysing blood samples
from health check-ups in non-hospitalised persons.
However, any healthy cohort effect would not affect the
internal validity of our study [11]. To our knowledge,
this is the first observational study utilising latent class
proportional hazards model to address disease-specific
survival in BC, taking into account CV death and other
death as competing events. As shown in our study, the
advantage of incorporating latent class analysis and mul-
tiple events in addition to proportional hazards regres-
sion is that it allows identification of subpopulations
within the cohort and final survival or hazard estimates
of the primary event. In other words, this method may
offer a suitable approach when dealing with survival
functions or hazard rates estimation in presence of com-
peting risks. A limitation of our study was the lack of
data representing older BC patients, which may partly
explain the low proportion of Class II. There was no in-
formation available on tumour characteristics, BC sus-
ceptibility genes, and treatment or other metabolic and
endocrine factors related to BC such as obesity and use
of hormonal replacement therapy. Although residual as-
sociations with unobserved covariates were captured by
our model through identification of latent classes,
underlying characteristics of these different subgroups of
BC patients may require further integration of other
relevant markers or baseline information.
Conclusion
The present study showed a weak association between
prediagnostic TG levels and BC death in the majority of
women with BC. On the other hand, glucose and TC
were strongly associated to mortality from causes apart
from BC in the remaining patients, among which shorter
overall survival was observed. Our study therefore dem-
onstrated heterogeneity in the association between glu-
cose, lipid markers, and BC survival when CV death and
other death were taken into account as competing out-
comes. This implies an involvement of perturbed lipid
metabolism in BC progression and a complex interaction
between baseline biological markers and co-morbidities
in determining BC survival which warrants mechanistic
investigations. Therefore, our findings highlight the im-
portance of considering cohort heterogeneity when
evaluating biological markers in relation to cause-
specific death.
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Table 4 Hazard ratios of death from BC, CV disease and other
causes by levels of glucose, TG, and TC for each latent class
Class I Class II
HRa 95 % CI HRa 95 % CI
BC death
Log
glucose
1.09 0.73, 1.63 0.84 0.45, 1.57
Log TG 1.87 1.01, 3.45 0.91 0.50, 1.68
Log TC 0.84 0.49, 1.45 1.02 0.53, 1.99
CV death
Log
glucose
1.02 0.55, 1.91 1.46 0.97, 2.20
Log TG 7.68 2.45, 24.02 0.71 0.40, 1.25
Log TC 0.86 0.32, 2.28 2.07 1.16, 3.69
Other death
Log
glucose
0.73 0.50, 1.05 2.26 1.50, 3.40
Log TG 1.69 0.95, 3.01 1.40 0.74, 2.64
Log TC 1.20 0.65, 2.24 0.45 0.19, 1.06
aAll covariates were included in a single model and adjusted for age at
diagnosis, SES (white collar, blue collar, unemployed or unknown) and fasting
status (fasting, non-fasting, unknown)
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